

# David Kremer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10246437/publications.pdf>

Version: 2024-02-01

35  
papers

1,081  
citations

516710

16  
h-index

414414

32  
g-index

35  
all docs

35  
docs citations

35  
times ranked

1352  
citing authors

#	ARTICLE	IF	CITATIONS
1	Human endogenous retrovirus type W envelope protein inhibits oligodendroglial precursor cell differentiation. <i>Annals of Neurology</i> , 2013, 74, 721-732.	5.3	155
2	The complex world of oligodendroglial differentiation inhibitors. <i>Annals of Neurology</i> , 2011, 69, 602-618.	5.3	119
3	Pushing Forward: Remyelination as the New Frontier in CNS Diseases. <i>Trends in Neurosciences</i> , 2016, 39, 246-263.	8.6	82
4	pHERV-W envelope protein fuels microglial cell-dependent damage of myelinated axons in multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 15216-15225.	7.1	78
5	The Molecular Basis for Remyelination Failure in Multiple Sclerosis. <i>Cells</i> , 2019, 8, 825.	4.1	71
6	Promoting remyelination in multiple sclerosis: Current drugs and future prospects. <i>Multiple Sclerosis Journal</i> , 2015, 21, 541-549.	3.0	63
7	The neutralizing antibody GNBAC1 abrogates HERV-W envelope protein-mediated oligodendroglial maturation blockade. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1200-1203.	3.0	54
8	p57kip2 is dynamically regulated in experimental autoimmune encephalomyelitis and interferes with oligodendroglial maturation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 9087-9092.	7.1	46
9	Current advancements in promoting remyelination in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 7-14.	3.0	41
10	Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study. <i>Multiple Sclerosis Journal</i> , 2022, 28, 429-440.	3.0	40
11	Teriflunomide promotes oligodendroglial differentiation and myelination. <i>Journal of Neuroinflammation</i> , 2018, 15, 76.	7.2	37
12	Oligodendroglial Maturation Is Dependent on Intracellular Protein Shuttling. <i>Journal of Neuroscience</i> , 2015, 35, 906-919.	3.6	34
13	Rescuing the negative impact of human endogenous retrovirus envelope protein on oligodendroglial differentiation and myelination. <i>Glia</i> , 2019, 67, 160-170.	4.9	31
14	Remyelination in multiple sclerosis: from concept to clinical trials. <i>Current Opinion in Neurology</i> , 2019, 32, 378-384.	3.6	28
15	An unmet clinical need: roads to remyelination in MS. <i>Neurological Research and Practice</i> , 2019, 1, 21.	2.0	19
16	CXCR7 Is Involved in Human Oligodendroglial Precursor Cell Maturation. <i>PLoS ONE</i> , 2016, 11, e0146503.	2.5	18
17	Managing Risks with Immune Therapies in Multiple Sclerosis. <i>Drug Safety</i> , 2019, 42, 633-647.	3.2	18
18	Cryptococcal meningoencephalitis in an IgG2-deficient patient with multiple sclerosis on fingolimod therapy for more than five years – case report. <i>BMC Neurology</i> , 2020, 20, 158.	1.8	18

#	ARTICLE	IF	CITATIONS
19	Neural Cell Responses Upon Exposure to Human Endogenous Retroviruses. <i>Frontiers in Genetics</i> , 2019, 10, 655.	2.3	17
20	Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 978-985.	1.9	17
21	Secretome Analysis of Mesenchymal Stem Cell Factors Fostering Oligodendroglial Differentiation of Neural Stem Cells In Vivo. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4350.	4.1	16
22	Drug Treatment of Clinically Isolated Syndrome. <i>CNS Drugs</i> , 2019, 33, 659-676.	5.9	12
23	Long-term follow-up of multiple sclerosis studies and outcomes from early treatment of clinically isolated syndrome in the BENEFIT 11 study. <i>Journal of Neurology</i> , 2020, 267, 308-316.	3.6	12
24	Drug repurposing for neuroregeneration in multiple sclerosis. <i>Neural Regeneration Research</i> , 2018, 13, 1366.	3.0	10
25	Neurological manifestations of severe acute respiratory syndrome coronavirus 2 "a controversy "gone viral"™. <i>Brain Communications</i> , 2020, 2, fcaa149.	3.3	7
26	Reply to Ruprecht and Mayer: Unearthing genomic fossils in the pathogenesis of multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 19793-19794.	7.1	6
27	The degree of cortical plasticity correlates with cognitive performance in patients with Multiple Sclerosis. <i>Brain Stimulation</i> , 2022, 15, 403-413.	1.6	6
28	Human endogenous retroviruses: ammunition for myeloid cells in neurodegenerative diseases?. <i>Neural Regeneration Research</i> , 2020, 15, 1043.	3.0	5
29	Prehistoric enemies within: The contribution of human endogenous retroviruses to neurological diseases. Meeting report: "Second International Workshop on Human Endogenous Retroviruses and Disease", Washington DC, March 13th and 14th 2017. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 15, 18-23.	2.0	4
30	ECTRIMS/ACTRIMS 2017: Closing in on neurorepair in progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 696-700.	3.0	4
31	Meeting report: "Human endogenous retroviruses: HERVs or transposable elements in autoimmune, chronic inflammatory and degenerative diseases or cancer", Lyon, France, november 5th and 6th 2019 "an MS scientist's digest. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102068.	2.0	4
32	Crosstalk of Microorganisms and Immune Responses in Autoimmune Neuroinflammation: A Focus on Regulatory T Cells. <i>Frontiers in Immunology</i> , 2021, 12, 747143.	4.8	3
33	Case Report: Persisting Lymphopenia During Neuropsychiatric Tumefactive Multiple Sclerosis Rebound Upon Fingolimod Withdrawal. <i>Frontiers in Neurology</i> , 2021, 12, 785180.	2.4	3
34	Nitrosative Stress Molecules in Multiple Sclerosis: A Meta-Analysis. <i>Biomedicines</i> , 2021, 9, 1899.	3.2	2
35	Case Report: Successful Stabilization of Marburg Variant Multiple Sclerosis With Ocrelizumab Following High-Dose Cyclophosphamide Rescue. <i>Frontiers in Neurology</i> , 2021, 12, 696807.	2.4	1